Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hLB-001 gene therapy in pediatric MMA (SUNRISE)
NCT04581785Phase 2Terminated
- Sponsor
- LogicBio Therapeutics
- Start
- May 2021
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of LB-001 in methylmalonic acidemia (MMA), sponsored by LogicBio Therapeutics. Started May 2021; status: terminated.
02
Drugs
LB-001
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on NCT04581785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581785.